April 15 (Reuters) - Johnson & Johnson JNJ.N:
J&J EXEC SAYS EXPECTS APPROVAL OF CAPLYTA LATER THIS YEAR AS AN ADJUNCTIVE TREATMENT FOR MAJOR DEPRESSIVE DISORDER - CONF CALL
J&J EXEC SAYS IMPLEMENTING A RESTRUCTURING PROGRAM TO SIMPLIFY AND FOCUS THE OPERATIONS OF ITS SURGERY BUSINESS - CONF CALL
J&J EXEC SAYS PLAN TO EXIT CERTAIN NON STRATEGIC PRODUCT LINES GLOBALLY & OPTIMIZE SELECT SITES ACROSS THE NETWORK FOR SURGERY BUSINESS
J&J EXEC SAYS CO EXPECTS SOME MODEST SHORT TERM REVENUE DISRUPTION IN SURGERY BUSINESS OF ABOUT $250 MILLION OVER THE NEXT TWO YEARS
J&J EXEC SAYS RESTRUCTURING PROGRAM FOR SURGERY BUSINESS IS EXPECTED TO BE COMPLETED IN 2027 WITH COST ESTIMATED AT ABOUT $900 MILLION
J&J CEO SAYS "NOT TARIFFS, BUT TAX POLICY" IS THE MOST EFFECTIVE WAY TO BUILD MANUFACTURING CAPACITY IN THE US FOR MEDICAL DEVICES AND PHARMACEUTICALS
J&J CEO SAYS PHARMACEUTICALS "TARIFFS CAN CREATE DISRUPTIONS IN THE SUPPLY CHAIN, LEADING TO SHORTAGES"
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。